Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Nephrology Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Nephrology Other
    Ultrafiltration Shown Superior to Diuretics in Patients With Severe Heart Failure: Presented at HFSA - (DGDispatch)
    Why Kidneys From Older Donors Do Not Last as Long as Those From Younger Individuals - (DGNews)
    NICE Releases New Guideline on Early Identification of Chronic Kidney Disease - (DGNews)
    Patients With Chronic Kidney Disease on Darbepoetin Therapy Do Not Require Dose-Adjustment for Weight: Presented at ACCP - (DGDispatch)
    Healthy People With Elevated Levels of Uric Acid at Risk of Kidney Disease - (DGNews)

    News archive

     Recent webcasts/CME - Nephrology Other
    • Improving the Standard of Care in Acute Hypertension
    • The State of the Science in Managing Systemic Lupus Erythematosus: Update From EULAR 2008
    • Understanding Current and Emerging Treatments for Systemic Lupus Erythematosus
    • Evaluating New Treatment Strategies for Lupus Nephritis
    • Pathophysiology of Clinical Disorders of Renal Tubular Electrolyte Reabsorption & Causes of Hypertension vs. Hypotension

      Webcasts/CME archive

       Recent cases - Nephrology Other
        Non-Healing Painful Ulcers in a Patient with Chronic Kidney Disease and Role of Sodium Thiosulfate: A Case Report
        Conservative Management of Grade 1V Renal Injury with Complete Transection: A Case Report
        Emphysematous Pyelonephritis, a Rare Cause of Pneumoperitoneum: A Case Report and Review of Literature
        Pelvo-Ureteric Junction Obstruction in the Lower Pole Moiety of a Duplex Kidney with an Associated Intraparenchymal Abscess: A Case Report
        Successful Transureteropyelostomy after Heminephrectomy of a Bilateral Hydronephrotic Horseshoe Kidney: A Case Report

        Cases archive
          




        my personal edition > nephrology other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Three Of 12 Patients Taking Pyridorin (Pyridoxamine Dihydrochloride) Convert From Macro- To Microalbuminuria: Presented at ASN

        By Maggie Schwarz
        Special to DG News

        PHILADELPHIA, PA -- November 3, 2002 -- The advanced glycation end product (AGE) inhibitor Pyridorin (pyridoxamine dihydrochloride) has potential in treating diabetic nephropathy, researchers reported here November 1 at the 35th Annual Meeting of the American Society of Nephrology (ASN).

        Dr. Thorsten P. Degenhardt and colleagues from BioStratum Incorporated, in Durham, North Carolina, United States, conducted a randomised, placebo-controlled trial including 12 patients with type 2 diabetes and macroalbuminuria greater than 300 mg/day.

        They randomised patients to receive Pyridorin or placebo at a 3 to 1 ratio and escalated the dose of Pyridorin based on tolerability, from 50 mg b.i.d. on days 1 through 7 to 250 mg b.i.d. on days 9 through 15, to 500 mg b.i.d. on days 17 through 44.

        Pharmacokinetic assessments were performed after the first (0 to 12 hours) and last (0 to 48 hours) dose of each dosing level. After the first dose of each dosing level, the time of maximum concentration was approximately 2.5 hours. The maximum drug concentration was 1 and 1.5 µg/hr/mL at 250 and 500 mg doses, respectively. Pharmacokinetic parameters observed after multiple dosings were not significantly different than after a single dose, indicating lack of drug accumulation, Dr. Degenhardt said.

        Pyridorin metabolism followed the known metabolic pathways for the B6 vitamer family, with pyridoxal and 4-pyridoxic acid being the primary detectable metabolites. No conversion to pyridoxine was detected.

        The researchers found all dose levels of Pyridorin were well tolerated, with no serious adverse events reported and no discontinuations due to an adverse event.

        Patients taking Pyridorin experienced an average decrease from baseline 24-hour urinary albumin excretion of 32 percent at day 45. Three patients receiving Pyridorin converted to microalbuminuria by the end of the trial.

        Pyridorin is in phase 2 clinical development for diabetic nephropathy and has inhibited both development and progression of diabetic nephropathy in animal models of type 1 and 2 diabetes.

        Dr. Thorsten concluded that Pyridorin holds promise in the treatment of diabetic nephropathy.



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send